{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:13:42Z","timestamp":1785932022370,"version":"3.56.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Current standard of care for ameloblastoma (conventional\/unicystic - mural type) usually mandates extensive bone resection that frequently necessitates immediate reconstruction with serious sequelae, especially among young patients. <jats:italic>BRAF<\/jats:italic>-mutated ameloblastomas can be targeted by BRAF inhibitors to markedly reduce their size, enabling conservative removal of residual tumor. We aimed to characterize the effect of post-treatment histomorphologic changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Study included 14 patients, 11 mandibular and three maxillary tumors. Cases with very minimal residual tumor were defined as near-complete response, while those with mostly vital residual tumor as partial response. The epithelium component was scored for architectural and cellular changes, stroma - for fibrosis, inflammation and new bone formation, on a 3-tired score system: 0\u2013no, 1\u2013focal and 3\u2013frequent changes. The mean scores of each parameter, total epithelium and total stroma were calculated and related to duration of treatment. Differences in the mean scores were investigated for mandibular tumors with near-complete response (<jats:italic>n<\/jats:italic>\u2009=\u20093) and partial response (<jats:italic>n<\/jats:italic>\u2009=\u20098).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were no significant differences in mean epithelium or stroma scores between tumors with near-complete and those with partial response (2.22\u2009<jats:italic>\u00b1<\/jats:italic>\u20090.68 <jats:italic>versus<\/jats:italic> 2.08\u2009<jats:italic>\u00b1<\/jats:italic>\u20090.43, <jats:italic>p<\/jats:italic>\u2009=\u20090.55; 1.41\u2009<jats:italic>\u00b1<\/jats:italic>\u20091.04 <jats:italic>versus<\/jats:italic> 1.43\u2009<jats:italic>\u00b1<\/jats:italic>\u20090.44, <jats:italic>p<\/jats:italic>\u2009=\u20090.27), suggesting that ameloblastomas have potential to undergo complete response to targeted treatment. This is probably dependent upon tumor\/patient\/treatment-related factors. Response to treatment appears to be predictable with neoplastic epithelium being first, while the stromal response increases during treatment, the entire process expanding over weeks-to-months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Albeit preliminary, these are the first comprehensive histomorphologic findings on BRAF-treated ameloblastomas. Analyzing the suggested parameters in tumors with partial response, should highlight which tumor component has responded\/failed to respond. This could serve as a basis for decision-taking toward subsequent steps in adjuvant treatment (e.g., follow-up, conservative surgery, modifications\/changes in treatment regimen, combinations of approaches), with a prime aim of jaw preservation and minimal risk of sequelae.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12105-024-01734-2","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T07:24:53Z","timestamp":1733124293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies \u2013 Pathological and Clinical Perspectives"],"prefix":"10.1007","volume":"18","author":[{"given":"Ariel","family":"Hirschhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirly","family":"Grynberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gadi Abebe","family":"Campino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dobriyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahl","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Yacobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Barshack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Toren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Vered","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"1734_CR1","volume-title":"WHO classification of head and neck tumours. Odontogenic and maxillofacial bone tumours","author":"M Vered","year":"2022","unstructured":"Vered M, Adebiyi KE, Heikinheimo K (2022) Ameloblastoma. In: Muller S, Odell EW, Tilakaratne WM (eds) WHO classification of head and neck tumours. Odontogenic and maxillofacial bone tumours. IARC, Lyon. in press"},{"key":"1734_CR2","volume-title":"Oral and maxillofacial pathology","author":"BW Neville","year":"2023","unstructured":"Neville BW, Damm DD, Allen CM, Chi AC (2023) Oral and maxillofacial pathology. Elsevier, St. Louis"},{"key":"1734_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/SCS.0000000000005840","volume":"31","author":"MR Borrelli","year":"2020","unstructured":"Borrelli MR, Hu MS, Longaker MT, Lorenz HP (2020) Tissue engineering and regenerative medicine in craniofacial reconstruction and facial aesthetics. J Craniofac Surg 31:15\u201327. https:\/\/doi.org\/10.1097\/SCS.0000000000005840","journal-title":"J Craniofac Surg"},{"key":"1734_CR4","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.1158\/1078-0432.CCR-14-1069","volume":"20","author":"NA Brown","year":"2014","unstructured":"Brown NA, Rolland D, McHugh JB, Weigelin HC, Zhao L, Lim MS, Lim MS, Elenitoba-Johnson KS, Betz BL (2014) Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clin Cancer Res 20:5517\u20135526. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1069","journal-title":"Clin Cancer Res"},{"key":"1734_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/path.4317","volume":"232","author":"KJ Kurppa","year":"2014","unstructured":"Kurppa KJ, Cat\u00f3n J, Morgan PR, Ristim\u00e4ki A, Ruhin B, Kellokoski J, Elenius K, Heikinheimo K (2014) High frequency of BRAF V600E mutations in ameloblastoma. J Pathol 232:492\u2013498. https:\/\/doi.org\/10.1002\/path.4317","journal-title":"J Pathol"},{"key":"1734_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.2986","volume":"46","author":"RT Sweeney","year":"2014","unstructured":"Sweeney RT, McClary AC, Myers et al (2014) Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet 46:722\u2013725. https:\/\/doi.org\/10.1038\/ng.2986","journal-title":"Nat Genet"},{"key":"1734_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/jnci\/dju378","volume":"107","author":"FJ Kaye","year":"2014","unstructured":"Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW (2014) Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. J Natl Cancer Inst 107:378. https:\/\/doi.org\/10.1093\/jnci\/dju378","journal-title":"J Natl Cancer Inst"},{"key":"1734_CR8","doi-asserted-by":"publisher","unstructured":"Faden DL, Algazi A Durable treatment of ameloblastoma with single agent BRAFi re: clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma (2016). J Natl Cancer Inst 109:djw190. https:\/\/doi.org\/10.1093\/jnci\/djw190","DOI":"10.1093\/jnci\/djw190"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.oooo.2015.12.016","volume":"122","author":"S Tan","year":"2016","unstructured":"Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB (2016) BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surg Oral Med Oral Pathol Oral Radiol 122:e5\u20137. https:\/\/doi.org\/10.1016\/j.oooo.2015.12.016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1734_CR10","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s12885-018-4802-y","volume":"18","author":"GS Fernandes","year":"2018","unstructured":"Fernandes GS, Girardi DM, Bernardes JPG, Fonseca FP, Fregnani ER (2018) Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. BMC Cancer 18:887. https:\/\/doi.org\/10.1186\/s12885-018-4802-y","journal-title":"BMC Cancer"},{"key":"1734_CR11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3389\/fonc.2019.0120","volume":"9","author":"M Brunet","year":"2019","unstructured":"Brunet M, Khalifa E, Italiano A (2019) Enabling precision medicine for rare head and neck tumors: the example of BRAF\/MEK targeting in patients with metastatic ameloblastoma. Front Oncol 9:1204. https:\/\/doi.org\/10.3389\/fonc.2019.0120","journal-title":"Front Oncol"},{"key":"1734_CR12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13256-019-2140-6","volume":"13","author":"M Broudic-Guibert","year":"2019","unstructured":"Broudic-Guibert M, Blay JY, Vazquez L, Evrard A, Karanian M, Ta\u00efeb S, Hoog-Labouret N, Oukhatar CMA, Boustany-Grenier R, Arnaud A (2019) Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. J Med Case Rep 13:245. https:\/\/doi.org\/10.1186\/s13256-019-2140-6","journal-title":"J Med Case Rep"},{"key":"1734_CR13","doi-asserted-by":"publisher","first-page":"105854","DOI":"10.1016\/j.oraloncology.2022.105854","volume":"128","author":"Z Abramson","year":"2022","unstructured":"Abramson Z, Dayton OL, Drane WE, Mendenhall WM, Kaye FJ (2022) Managing stage 4 ameloblastoma with dual BRAF\/MEK inhibition: a case report with 8-year clinical follow-up. Oral Oncol 128:105854. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105854","journal-title":"Oral Oncol"},{"key":"1734_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00223-023-01177-x","volume":"114","author":"K Corbett","year":"2024","unstructured":"Corbett K, Ruether D, Seiden-Long I, Kline G (2024) Resolution of PTHrP-mediated hypercalcemia following treatment with dual BRAF\/MEK inhibition for BRAFV600E-positive metastatic ameloblastoma. Calcif Tissue Int 114:444\u2013449. https:\/\/doi.org\/10.1007\/s00223-023-01177-x","journal-title":"Calcif Tissue Int"},{"key":"1734_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/term.3254","volume":"15","author":"A Hirschhorn","year":"2021","unstructured":"Hirschhorn A, Campino GA, Vered M, Greenberg G, Yacobi R, Yahalom R, Barshack I, Toren A, Amariglio N, Rechavi G (2021) Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration. J Tissue Eng Regen Med 15:1155\u20131161. https:\/\/doi.org\/10.1002\/term.3254","journal-title":"J Tissue Eng Regen Med"},{"key":"1734_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jnci\/djad232","volume":"116","author":"S Grynberg","year":"2024","unstructured":"Grynberg S, Vered M, Shapira-Frommer, Asher N, Ben-Betzalel G, Stoff R, Steinberg Y, Amariglio N, Greenberg G, Barshack I, Toren A, Yahalom R, Schachter J, Rechavi G, Hirschhorn A, Abebe Campino G (2024) Neoadjuvant BRAF targeted therapy for ameloblastoma of the mandible: an organ preservation approach. J Natl Cancer Inst 116:539\u2013546. https:\/\/doi.org\/10.1093\/jnci\/djad232","journal-title":"J Natl Cancer Inst"},{"key":"1734_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/27325016211005126","volume":"2","author":"S Daws","year":"2021","unstructured":"Daws S, Chaiyasate K, Lehal A (2021) Treatment of a BRAF V600E positive ameloblastoma in a pediatric patient with MEK inhibitor monotherapy. Face 2:179\u2013182. https:\/\/doi.org\/10.1177\/27325016211005126","journal-title":"Face"},{"key":"1734_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/DAD.0b013e318263f232","volume":"35","author":"JL Curry","year":"2013","unstructured":"Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG (2013) Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol 35:125\u2013128. https:\/\/doi.org\/10.1097\/DAD.0b013e318263f232","journal-title":"Am J Dermatopathol"},{"key":"1734_CR19","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/life12091332","volume":"12","author":"H Safwan-Zaiter","year":"2022","unstructured":"Safwan-Zaiter H, Wagner N, Wagner KD (2022) P16INK4A - more than a senescence marker. Life (Basel) 12:1332. https:\/\/doi.org\/10.3390\/life12091332","journal-title":"Life (Basel)"},{"key":"1734_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.humpath.2009.12.002","volume":"132","author":"N Wajapeyee","year":"2008","unstructured":"Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 132:363\u2013374. https:\/\/doi.org\/10.1016\/j.humpath.2009.12.002","journal-title":"Cell"},{"key":"1734_CR21","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41467-020-16475-3","volume":"11","author":"N Azazmeh","year":"2020","unstructured":"Azazmeh N, Assouline B, Winter E, Ruppo S, Nevo Y, Maly A et al (2020) Chronic expression of p16INK4a in the epidermis induces wnt-mediated hyperplasia and promotes tumor initiation. Nat Commun 11:2711. https:\/\/doi.org\/10.1038\/s41467-020-16475-3","journal-title":"Nat Commun"},{"key":"1734_CR22","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1038\/s41467-020-16475-3","volume":"11","author":"C Capparelli","year":"2012","unstructured":"Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Meir K, Witkiewicz AK, Cohen J, Rizou SV, Pikarsky E, Luxenburg C, Gorgoulis VG, Ben-Porath I (2012) CDK inhibitors (p16\/p19\/p21) induce senescence and autophagy in cancer-associated fibroblasts, fueling tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 11:3599\u20133610. https:\/\/doi.org\/10.1038\/s41467-020-16475-3","journal-title":"Cell Cycle"},{"key":"1734_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s43587-021-00098-4","volume":"1","author":"Y Aman","year":"2021","unstructured":"Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, Palikaras K, Simonsen A, Johansen T, Tavernarakis N, Rubinsztein DC, Partridge L, Kroemer G, Labbadia J, Fang EF (2021) Autophagy in healthy aging and disease. Nat Aging 1:634\u2013650. https:\/\/doi.org\/10.1038\/s43587-021-00098-4","journal-title":"Nat Aging"},{"key":"1734_CR24","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3390\/biology11121731","volume":"11","author":"AM Andrade","year":"2022","unstructured":"Andrade AM, Sun M, Gasek NS, Hargis GR, Sharafieh R, Xu M (2022) Role of senescent cells in cutaneous wound healing. Biology (Basel) 11:1731. https:\/\/doi.org\/10.3390\/biology11121731","journal-title":"Biology (Basel)"},{"key":"1734_CR25","doi-asserted-by":"publisher","first-page":"661737","DOI":"10.3389\/fimmu.2021.661737","volume":"12","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE (2021) Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Front Immunol 12:661737. https:\/\/doi.org\/10.3389\/fimmu.2021.661737","journal-title":"Front Immunol"},{"key":"1734_CR26","unstructured":"Sciubba JS, Fantasia JE, Kahn LB (2001) Atlas of tumor pathology. Tumors and cysts of the jaws. 3rd series, Fascicle 29. Armed Forces Institute of Pathology, Washington, D.C"},{"key":"1734_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1034\/j.1600-0749.2002.02036.x","volume":"15","author":"DC Bennett","year":"2002","unstructured":"Bennett DC, Medrano EE (2002) Molecular regulation of melanocyte senescence. Pigment Cell Res 15:242\u2013250. https:\/\/doi.org\/10.1034\/j.1600-0749.2002.02036.x","journal-title":"Pigment Cell Res"},{"key":"1734_CR28","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1016\/j.oooo.2019.08.009","volume":"129","author":"A Morice","year":"2020","unstructured":"Morice A, Neiva C, Fabre M, Spina P, Jouenne F, Galliani E, Vazquez MP, Picard (2020) Conservative management is effective in unicystic ameloblastoma occurring from the neonatal period: a case report and a literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 129:e234\u2013e242. https:\/\/doi.org\/10.1016\/j.oooo.2019.08.009","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1734_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1074\/jbc.C400538200","volume":"280","author":"S Kamada","year":"2005","unstructured":"Kamada S, Kikkawa U, Tsujimoto Y, Hunter T (2005) Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). J Biol Chem 280:857\u2013860. https:\/\/doi.org\/10.1074\/jbc.C400538200","journal-title":"J Biol Chem"},{"key":"1734_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jamcollsurg.2014.12.057","volume":"220","author":"AS Johnson","year":"2015","unstructured":"Johnson AS, Crandall H, Dahlman K, Kelley MC (2015) Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. J Am Coll Surg 220:581\u2013593e1. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2014.12.057","journal-title":"J Am Coll Surg"},{"key":"1734_CR31","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cen.14679","volume":"96","author":"HC McCrary","year":"2022","unstructured":"McCrary HC, Aoki J, Huang Y, Chadwick B, Kerrigan K, Witt B, Hunt JP, Abraham D (2022) Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol (Oxf) 96:734\u2013742. https:\/\/doi.org\/10.1111\/cen.14679","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1734_CR32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00405-023-07827-y","volume":"280","author":"E Maurer","year":"2023","unstructured":"Maurer E, Eilsberger F, W\u00e4chter S, Riera Knorrenschild J, Pehl A, Holzer K, Neubauer A, Luster M, Bartsch DK (2023) Mutation-based, short-term neoadjuvant treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol 280:1509\u20131518. https:\/\/doi.org\/10.1007\/s00405-023-07827-y","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"1734_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/bjc.1994.303","volume":"70","author":"SA Rasbridge","year":"1994","unstructured":"Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR (1994) The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 70:335\u2013341. https:\/\/doi.org\/10.1038\/bjc.1994.303","journal-title":"Br J Cancer"},{"key":"1734_CR34","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/hed.27294","volume":"45","author":"JC Gates","year":"2023","unstructured":"Gates JC, Clark AP, Cherkas E, Shreenivas AV, Kraus D, Danzinger N, Huang RSP, Johnson J, Ross JS (2023) Genomic profiling and precision medicine in complex ameloblastoma. Head Neck 45:816\u2013826. https:\/\/doi.org\/10.1002\/hed.27294","journal-title":"Head Neck"},{"key":"1734_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1034\/j.1600-0714.2001.300509.x","volume":"30","author":"H Kumamoto","year":"2001","unstructured":"Kumamoto H, Kimi K, Ooya K (2001) Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 30:309\u2013315. https:\/\/doi.org\/10.1034\/j.1600-0714.2001.300509.x","journal-title":"J Oral Pathol Med"},{"key":"1734_CR36","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/j.oraloncology.2009.08.007","volume":"45","author":"Q Tao","year":"2009","unstructured":"Tao Q, Lv B, Qiao B, Zheng CQ, Chen ZF (2009) Immortalization of ameloblastoma cells via reactivation of telomerase function: phenotypic and molecular characteristics. Oral Oncol 45:e239\u2013244. https:\/\/doi.org\/10.1016\/j.oraloncology.2009.08.007","journal-title":"Oral Oncol"},{"key":"1734_CR37","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.archoralbio.2009.07.006","volume":"54","author":"PR Moreira","year":"2009","unstructured":"Moreira PR, Guimar\u00e3es MM, Gomes CC, Diniz MG, Brito JA, de Castro WH, Gomez RS (2009) Methylation frequencies of cell-cycle associated genes in epithelial odontogenic tumours. Arch Oral Biol 54:893\u2013897. https:\/\/doi.org\/10.1016\/j.archoralbio.2009.07.006","journal-title":"Arch Oral Biol"},{"key":"1734_CR38","doi-asserted-by":"publisher","unstructured":"Singh T, Chandu A, Clement J, Angel C (2017) Immunohistochemistry of five molecular markers for typing and management of ameloblastomas: a retrospective analysis of 40 cases. J Maxillofac Oral Surg 16:65\u201370. https:\/\/doi.org\/10.1007\/s12663-016-0923-5","DOI":"10.1007\/s12663-016-0923-5"},{"key":"1734_CR39","first-page":"363","volume":"55","author":"DA Olimid","year":"2014","unstructured":"Olimid DA, Florescu AM, Cernea D, Georgescu CC, M\u0103rg\u0103ritescu C, Simionescu CE, Stepan AE (2014) The evaluation of p16 and Ki67 immunoexpression in ameloblastomas. Rom J Morphol Embryol 55:363\u2013367","journal-title":"Rom J Morphol Embryol"},{"key":"1734_CR40","doi-asserted-by":"publisher","first-page":"djv406","DOI":"10.1093\/jnci\/djv406","volume":"108","author":"AE Vilgelm","year":"2015","unstructured":"Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A (2015) Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment. J Natl Cancer Inst 108:djv406. https:\/\/doi.org\/10.1093\/jnci\/djv406","journal-title":"J Natl Cancer Inst"},{"key":"1734_CR41","doi-asserted-by":"publisher","first-page":"e17714","DOI":"10.1016\/j.heliyon.2023.e17714","volume":"9","author":"J Peng","year":"2023","unstructured":"Peng J, Lin Z, Chen W, Ruan J, Deng F, Yao L, Rao M, Xiong X, Xu S, Zhang X, Liu X, Sun X (2023) Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance. Heliyon 9:e17714. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17714","journal-title":"Heliyon"},{"key":"1734_CR42","doi-asserted-by":"publisher","first-page":"104712","DOI":"10.1016\/j.yexmp.2021.104712","volume":"123","author":"G Karpathiou","year":"2021","unstructured":"Karpathiou G, Hamlat M, Dridi M, Forest F, Papoudou-Bai A, Dumollard JM, Peoc\u2019h M (2021) Autophagy and immune microenvironment in craniopharyngioma and ameloblastoma. Exp Mol Pathol 123:104712. https:\/\/doi.org\/10.1016\/j.yexmp.2021.104712","journal-title":"Exp Mol Pathol"},{"key":"1734_CR43","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2559.2008.03127.x","volume":"53","author":"GS Sathi","year":"2008","unstructured":"Sathi GS, Nagatsuka H, Tamamura R, Fujii M, Gunduz M, Inoue M, Rivera RS, Nagai N (2008) Stromal cells promote bone invasion by suppressing bone formation in ameloblastoma. Histopathology 53:458\u2013467. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03127.x","journal-title":"Histopathology"},{"key":"1734_CR44","doi-asserted-by":"publisher","first-page":"107335","DOI":"10.1016\/j.carpath.2021.107335","volume":"52","author":"G Karpathiou","year":"2021","unstructured":"Karpathiou G, Dumollard JM, Camy F, Sramek V, Dridi M, Picot T, Mobarki M, Peoc\u2019h M (2021) Senescence, immune microenvironment, and vascularization in cardiac myxomas. Cardiovasc Pathol 52:107335. https:\/\/doi.org\/10.1016\/j.carpath.2021.107335","journal-title":"Cardiovasc Pathol"},{"key":"1734_CR45","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4000","volume":"21","author":"BG Childs","year":"2015","unstructured":"Childs BG, Durik M, Baker DJ, van Deursen JM (2015) Cellular senescence in aging and age-related disease: from mechanisms to therapy. Nat Med 21:1424\u20131435. https:\/\/doi.org\/10.1038\/nm.4000","journal-title":"Nat Med"},{"key":"1734_CR46","doi-asserted-by":"publisher","unstructured":"Wang D, Wang H (2022) Cellular senescence in bone. Physiology. IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.101803","DOI":"10.5772\/intechopen.101803"},{"key":"1734_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjd.12268","volume":"169","author":"A Adam","year":"2013","unstructured":"Adam A, Thomas L, Bories N, Zaharia D, Balme B, Freymond N, Dalle S (2013) Sarcoidosis associated with vemurafenib. Br J Dermatol 169:206\u2013208. https:\/\/doi.org\/10.1111\/bjd.12268","journal-title":"Br J Dermatol"},{"key":"1734_CR48","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/annonc\/mdy218","volume":"29","author":"TR Cottrell","year":"2018","unstructured":"Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29:1853\u20131860. https:\/\/doi.org\/10.1093\/annonc\/mdy218","journal-title":"Ann Oncol"},{"key":"1734_CR49","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.annonc.2021.03.006","volume":"32","author":"RV Rawson","year":"2021","unstructured":"Rawson RV, Adhikari C, Bierman C, Lo SN, Shklovskaya E, Rozeman EA, Menzies AM, van Akkooi ACJ, Shannon KF, Gonzalez M, Guminski AD, Tetzlaff MT, Stretch JR, Eriksson H, van Thienen JV, Wouters MW, Haanen JBAG, Klop WMC, Zuur CL, van Houdt WJ, Nieweg OE, Ch\u2019ng S, Rizos H, Saw RPM, Spillane AJ, Wilmott JS, Blank CU, Long GV, van de Wiel BA, Scolyer RA (2021) Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Ann Oncol 32:766\u2013777. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.006","journal-title":"Ann Oncol"},{"key":"1734_CR50","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.bjoms.2016.07.017","volume":"54","author":"J Haq","year":"2016","unstructured":"Haq J, Siddiqui S, McGurk M (2016) Argument for the conservative management of mandibular ameloblastomas. Br J Oral Maxillofac Surg 54:1001\u20131005. https:\/\/doi.org\/10.1016\/j.bjoms.2016.07.017","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1734_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/s0301-0503(85)80021-7","volume":"13","author":"H M\u00fcller","year":"1985","unstructured":"M\u00fcller H, Slootweg PJ (1985) The ameloblastoma, the controversial approach to therapy. J Maxillofac Surg 13:79\u201384. https:\/\/doi.org\/10.1016\/s0301-0503(85)80021-7","journal-title":"J Maxillofac Surg"},{"key":"1734_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijom.2015.12.016","volume":"45","author":"A Almeida Rde","year":"2016","unstructured":"Almeida Rde A, Andrade ES, Barbalho JC, Vajgel A, Vasconcelos BC (2016) Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis. Int J Oral Maxillofac Surg 45:359\u2013367. https:\/\/doi.org\/10.1016\/j.ijom.2015.12.016","journal-title":"Int J Oral Maxillofac Surg"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-024-01734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-024-01734-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-024-01734-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:07:46Z","timestamp":1736348866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-024-01734-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s12105-024-01734-2","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standard. The study was approved by our local IRB, SMC-9405-22.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants (or their parent or legal guardian in the case of children under 16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"For this type of study consent for publication is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"129"}}